Supernus Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Supernus Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 126.4 times. Higher than almost all Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 8% in 3 years, but profit fell: $192 less profit per $100 of extra sales. Lower than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
100×+Over the last 3 years its own operating cash covered its investment spending (capex) 126.4 times.
Higher than almost all Healthcare companies in United States.
Cash Locked Ratio
$37For every $100 of sales, $37 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $37 tied up three years earlier.
More money tied up than 78% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
−$192Sales grew 8% in 3 years, but profit fell: $192 less profit per $100 of extra sales.
Lower than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+8% / -15%In 3 years sales changed by +8% while total assets changed by -15%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
4.5×Debt due within a year is covered 4.5 times by its yearly operating cash.
Higher than 79% of Healthcare companies in United States.
Cash Cushion Ratio
+11%Cash, after subtracting all debt, equals 11% of its market value (net cash).
Higher than 51% of Healthcare companies in United States.
Tangible Assets Ratio
52%Of every $100 the company owns, $52 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 77% of Healthcare companies in United States.
Tangible Net Worth Ratio
35%Of every $100 of net worth, $35 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 60% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Supernus Pharmaceuticals, Inc. made a loss over the last year. Supernus Pharmaceuticals, Inc. owes $0.28 for every $1 it owns. Supernus Pharmaceuticals, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSupernus Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.30The share price is 2.30 times Supernus Pharmaceuticals, Inc.'s book value per share, lower than 53% of Healthcare companies in United States.
Market cap
$2.4 BThe total market value of all of Supernus Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 78% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.0 BWhat Supernus Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$17.71Net worth divided by the number of shares. The share price of $40.70 is 2.3 times this, which is the P/B above.
Return on equity (ROE)
-10.5%Supernus Pharmaceuticals, Inc. lost 10.5% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.
Owes vs Owns
0.28×Supernus Pharmaceuticals, Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Dividend yield
NoneSupernus Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+9%Revenue rose 9% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Profit growth
LossSupernus Pharmaceuticals, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-5.4%Supernus Pharmaceuticals, Inc. lost $5 for every $100 of revenue.
Cash vs debt
Net cashSupernus Pharmaceuticals, Inc. held $268 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Supernus Pharmaceuticals, Inc.: $2.4 B ÷ $1.0 B (30 Jun 2026) = 2.3.
What is Supernus Pharmaceuticals, Inc.'s return on equity?
Supernus Pharmaceuticals, Inc. lost 10.5% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.
How much does Supernus Pharmaceuticals, Inc. owe compared with what it owns?
Supernus Pharmaceuticals, Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Does Supernus Pharmaceuticals, Inc. pay a dividend?
No. Supernus Pharmaceuticals, Inc. does not currently pay a dividend.
Is Supernus Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 9% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.